Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
Condition(s):RosaceaLast Updated:March 15, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):RosaceaLast Updated:March 15, 2024Recruiting
Condition(s):Cold Induced Headache; Brain Freeze; Cold Induced Cephalgia; HeadacheLast Updated:March 15, 2024Not yet recruiting
Condition(s):Ultraviolet B Radiation; Microvesicle ParticlesLast Updated:February 24, 2023Completed
Condition(s):Physician-Patient Relations; Diabetes Mellitus, Type 2Last Updated:March 5, 2024Withdrawn
Condition(s):Imipramine; Photodynamic Therapy; Actinic KeratosisLast Updated:April 19, 2023Recruiting
Condition(s):Respiratory Failure; Hypotension and Shock; Hypotension on Induction; Intubation Complication; Anesthesia Intubation ComplicationLast Updated:April 18, 2023Recruiting
Condition(s):Pruritus; Skin DisorderLast Updated:March 6, 2024Completed
Condition(s):PsoriasisLast Updated:April 21, 2023Completed
Condition(s):Photosensitivity; Microvesicle ParticleLast Updated:March 4, 2024Recruiting
Condition(s):Hypertension, Pregnancy-InducedLast Updated:October 23, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.